Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts
Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results...
AstraZeneca’s Soriot Discusses US BioSecure Act’s Impact Amid China Expansion Plans
Pascal Soriot, CEO of AstraZeneca (NASDAQ: AZN), addressed the potential implications of the US BioSecure...
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into...
HutchMed’s Orpathys Files for Expanded Indication in NSCLC Treatment in China
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the National Medical Products Administration...
Astellas Pharma’s Padcev Combo Therapy Accepted for Review in China for Urothelial Carcinoma
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that China’s Center...
China Unveils Management Measures to Strengthen National Health Emergency Teams
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...
China’s NHC Mandates Enhanced Management and Accessibility of Midwifery Services
The National Health Commission (NHC) has issued a notification with the aim of enhancing the...
AstraZeneca’s Tralokinumab Trial Data Spurs Development of Brainomix’s e-Lung Software
AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic...
BeiGene Terminates Partnership with Shoreline Therapeutics for NK Cell Therapies
A close examination of BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) recent annual report has...
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...
Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report...
CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand
CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for...
Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies
Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced...
Tianjin University Team Develops Self-Sustaining Na-O2 Battery for Implantable Devices
Researchers at China’s Tianjin University of Technology have made a groundbreaking advancement with the development...
Zai Lab and Novocure Report Positive Phase III Results for TTFields in NSCLC Brain Metastases
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, and Novocure...
Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai
Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China,...
Jiangsu Hengrui Receives NMPA Approval for SHR-7631 ADC Clinical Study in Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...